+432.9%
SNXX vs MRNA
+202.7%
+230.3%
-85.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +23.4% | -2.2% | +25.6% | +23.3% |
| 7D | +34.9% | +5.5% | +29.4% | +35.0% |
| 30D | +52.5% | +158.7% | -106.2% | +50.2% |
| 3M | -41.3% | +182.1% | -223.5% | -49.9% |
| 6M | +293.8% | +151.8% | +141.9% | +238.8% |
| All | +432.9% | +202.7% | +230.3% | +475.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling